A new silver sulfadiazine water soluble gel

Gear, Andrew J.L.; Hellewell, Timothy B.; Wright, Heather Harris; Mazzarese, Peter M.; Arnold, Peter; Rodeheaver, George T.; Edlich, Richard F.

doi:10.1016/s0305-4179(97)89763-x

Cited by 50 publications

(18 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many silver complexes are sparingly soluble in common solvents, especially water, which limits their uses in ointments and creams, as is the case of the most used topical antibacterial agent silversulfadiazine (SSD) [6]. The mechanisms of antibacterial action of the silver complexes have been scarcely described, although there are three possibilities: (i) interference with electron transport; (ii) inhibition of bacterial deoxyribonucleic acid (DNA) replication caused by the silver ion moiety, and (iii) modification of the bacterial cell membrane [7,8].…”

Section: Introductionmentioning

confidence: 99%

Synthesis, X-ray structure and antimycobacterial activity of silver complexes with α-hydroxycarboxylic acids

Cuin

Massabni

Leite

et al. 2007

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Synthesis, X-ray structure and antimycobacterial activity of silver complexes with α-hydroxycarboxylic acids

Cuin

Massabni

Leite

et al. 2007

Journal of Inorganic Biochemistry

View full text Add to dashboard Cite

“…The toxicity of silver used in clinical materials is reported to be minimal, with the notable rare cosmetic side effect of gray skin known as argyria (23). The toxicity of silver compounds, however, can often be linked to the carrier molecules (13). Consequently, the rational design of a new silver-based antimicrobial must ideally include coordination of the use of the bioactive metal with a nontoxic carrier.…”

mentioning

confidence: 99%

In Vitro and Murine Efficacy and Toxicity Studies of Nebulized SCC1, a Methylated Caffeine-Silver(I) Complex, for Treatment of Pulmonary Infections

Cannon¹,

Hogue²,

Vajravelu³

et al. 2009

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The expanding clinical challenge of respiratory tract infections due to resistant bacteria necessitates the development of new forms of therapy. The development of a compound composed of silver coupled to a methylated caffeine carrier (silver carbene complex 1 [SCC1]) that demonstrated in vitro efficacy against bacteria, including drug-resistant organisms, isolated from patients with respiratory tract infections was described previously. The findings of current in vitro studies now suggest that bactericidal concentrations of SCC1 are not toxic to airway epithelial cells in primary culture. Thus, it was hypothesized that SCC1 could be administered by the aerosolized route to concentrate delivery to the lung while minimizing systemic toxicity. In vivo, aerosolized SCC1 delivered to mice resulted in mild aversion behavior, but it was otherwise well tolerated and did not cause lung inflammation following administration over a 5-day period. The therapeutic efficacy of SCC1 compared to that of water was shown in a 3-day prophylaxis protocol, in which mice infected with a clinical strain of Pseudomonas aeruginosa had increased survival, decreased amounts of bacteria in the lung, and a lower prevalence of bacteremia. Similarly, by using an airway infection model in which bacteria were impacted in the airways by agarose beads, the administration of SCC1 was significantly superior to water in decreasing the lung bacterial burden and the levels of bacteremia and markers of airway inflammation. These observations indicate that aerosolized SCC1, a novel antimicrobial agent, warrants further study as a potential therapy for bacterial respiratory tract infections.

show abstract

“…Donor partial thickness burns, despite recognized disadvantages such as the formation of a pseudo-eschar,14,15 allergic reactions to the compound,…”

mentioning

confidence: 99%

Results of an Internet Survey on the Treatment of Partial Thickness Burns, Full Thickness Burns, and Donor Sites

Hermans¹

2007

Journal of Burn Care & Research

View full text Add to dashboard Cite

The objective of this study was to analyze which materials and methods are used for the management of partial and full thickness burns, as well as donor sites. An Internet survey was used to poll directors of burn centers around the world on their preferences for local treatment of different types of burns and donor sites. Results were tabulated and expressed as a percentage of the total number of answers for a given indication. Although many new wound care materials have been launched in the last decade, few of these actually are used widely. The most commonly used materials for partial thickness burns and donor sites are still silver sulphadiazine 1% cream, other antimicrobial ointments and creams and impregnated gauze type dressings. Of the newly available treatment modalities, only two silver dressings were chosen frequently as a primary option for the management of partial thickness burns and donor sites. For full thickness burns, the primary choice is excision and grafting. The diversity of dressings and techniques indicated as preferred in this survey, including many that are known to have side effects, indicates that there is no consensus on topical treatment of partial thickness burns and donor sites. Many respondents prefer "tried and true" materials over newer dressings, particularly if the latter have not been tested in a clinical trial.

show abstract

A new silver sulfadiazine water soluble gel

Cited by 50 publications

References 7 publications

Synthesis, X-ray structure and antimycobacterial activity of silver complexes with α-hydroxycarboxylic acids

Synthesis, X-ray structure and antimycobacterial activity of silver complexes with α-hydroxycarboxylic acids

In Vitro and Murine Efficacy and Toxicity Studies of Nebulized SCC1, a Methylated Caffeine-Silver(I) Complex, for Treatment of Pulmonary Infections

Results of an Internet Survey on the Treatment of Partial Thickness Burns, Full Thickness Burns, and Donor Sites

Contact Info

Product

Resources

About